Welcome to Anhui Poly Pharm. Co., Ltd.
language
中文 EN

A successful conclusion on the 22nd CPHI&PMEC China 2024, Looking forward to gathering again next time!

On June 19-21, 2024, the 22nd CPHI&PMEC China was grandly opened at the Shanghai New International Expo Center.

Anhui Poly Pharm. Co., Ltd. has attracted widespread attention from the industry due to its technological service platform advantages in the fields of iodine/gadolinium contrast agents and synthetic biology, as well as CMO/CDMO services that comply with European and US cGMP standards. In addition, Poly Pharm. has rich experience in international R&D, registration, and sales.

At this exhibition, Anhui Poly fully showcased its API business, including API sales, CMO, and CDMO services. The management of the company, including General Manager Dr. Nie, Deputy General Manager of Sales Mr. Hu, Director of API Sales Mrs. Xue, Director of Industrialization Research Institute Dr. Zhou, and Director of Biotechnology Research Institute Dr. Chai, personally attended the exhibition, had in-depth face-to-face communication with customers, and answered their inquiries.

微信图片_20240625091418.jpg

1、Anhui Poly Pharm

Anhui Poly Pharm. Co., Ltd. is a high-end API pharmaceutical base wholly owned by Poly Pharm. Group, committed to providing high-quality characteristic APIs and services for chemical synthesis and biosynthesis to the global pharmaceutical, health, and skincare fields.

The company is equipped with modern instruments and production equipment. At present, there are 9 production lines in 3 production workshops, a total of 357 multi-functional equipment, including advanced equipment such as ultrafiltration, nanofiltration, freeze-drying, centrifugation, three in one, DAC column, spray drying, automatic subcontracting, etc. Establish a strict cGMP quality system and high standard EHS system for high-end APIs in Europe and US, ensure product quality, and provide sustainable and high-quality services.

 

2、Advantage Products

Featured Products: Anhui Poly, on the one hand, relies on existing characteristic technology platforms to continuously optimize processes, reduce costs, and improve quality. It has successfully completed the R&D and industrial transformation of a series of products such as Gadoterate meglumine, gadoteridol, Gadobutrol, Ioversol, Iohexol, Iopamidol, Iodixanol, Iomeprol, Iopromide, and ethiodized oil, and achieved the commercialization of characteristic APIs such as contrast agents. On the other hand, it aims at synthetic biology, embrace the trend of scientific development, and build a green industry. The company has successfully developed the API Semaglutide through synthetic biology technology. The product is fermented by genetically engineered strains to obtain a peptide main chain, which is then obtained through a two-step chemical reaction. The purity of the product reaches over 98%. At present, the company has completed the large-scale production of high-purity raw materials and can meet the requirements for external supply. At the same time, the key excipient SNAC used in oral smeglutide preparations has commercial production capacity; And has submitted the DMF document (DMF number: 039651) to the US FDA. But it cannot be commercially supplied before the patent expires.

Advantage Products: Desloratadine, Dobutamine Hydrochloride, Magnesium Hydroxide, Sodium Nitroprusside, Voriconazole, L-Cysteine, Apremilast, Cyclophosphamide, Tecovirimat, Crisaborole, Brincidofovir, Memantine Hydrochloride, etc.

Anhui Poly’s products have attracted numerous domestic and foreign merchants to stop and consult and negotiate. Through on-site communication and exchange, we gain a deeper understanding of the needs of existing customers for better service, At the same time, effective potential customer information was also collected, further understanding the latest market trends and demands of the product, and promoting new cooperation intentions.

资源 4.png

3、Negotiation and Cooperation

资源 2.png

General Manager Dr. Nie, Deputy General Manager of Sales Mr. Hu, Director of API Sales Mrs. Xue, Talking with customers together with its sales team.

资源 3.png

Director of Industrialization Research Institute Dr. Zhou, and Director of Biotechnology Research Institute Dr. Chai, were receiving the customers on-site.

资源 1.png

We would like to express our sincere gratitude to our new and old customers who have provided long-term support and attention to Poly Pharm. Your continued support is the source of our development. Anhui Poly Pharm. will wholeheartedly provide more professional and thoughtful API services to more customers.